SeaStar Medical Holding Corporation (ICU) Q3 Revenue Rose 247% to $0.6M
SeaStar Medical (ICU) reported Q3 2026 revenue of $0.6M, up 247% YoY. Net loss increased to $4.5M from $3.5M, with $4.0M cash on hand. The company is in early commercial stage, growing QUELIMMUNE sales and advancing a pivotal trial.
How this was made

The 30-second read
Why it matters
The numbers provide fresh data for traders assessing short‑term price moves; the trial outcome could be a catalyst.
Market read
First‑time earnings disclosure for a micro‑cap; modest trading relevance.
What to watch
Potential impact of the pending NEUTRALIZE‑AKI trial results on future valuation.
Background
SeaStar Medical Holding Corp released its Q3 2026 earnings, showing a dramatic revenue increase but deeper losses.
Ticker impact
Q3 2026 revenue rose 247% to $0.6M and net loss widened, providing the first public disclosure of the company's quarterly results.
potential modest upside as investors price the revenue growth, tempered by concerns over expanding losses
Revenue growth is significant for a micro‑cap, yet the loss expansion suggests cash burn remains a risk.
Market effects
Highlights growth potential in niche medical device segment but underscores profitability challenges.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance beyond niche biotech interest.
Counterpoint
The revenue surge may be unsustainable; focus on cash burn and upcoming trial results.
Key entities
- companySeaStar Medical Holding Corp
Micro‑cap medical device firm reporting Q3 results.